Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
41 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Nonstructural Protein 4B (NS4B) - Pipeline Review, H1 2016', provides in depth analysis on Nonstructural Protein 4B (NS4B) targeted pipeline therapeutics. The report provides comprehensive information on the Nonstructural Protein 4B (NS4B), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Nonstructural Protein 4B (NS4B) - The report reviews Nonstructural Protein 4B (NS4B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Nonstructural Protein 4B (NS4B) targeted therapeutics and enlists all their major and minor projects - The report assesses Nonstructural Protein 4B (NS4B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Nonstructural Protein 4B (NS4B) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Nonstructural Protein 4B (NS4B) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Nonstructural Protein 4B (NS4B) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Nonstructural Protein 4B (NS4B) Overview 6 Therapeutics Development 7 Nonstructural Protein 4B (NS4B) - Products under Development by Stage of Development 7 Nonstructural Protein 4B (NS4B) - Products under Development by Therapy Area 8 Nonstructural Protein 4B (NS4B) - Products under Development by Indication 9 Nonstructural Protein 4B (NS4B) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Nonstructural Protein 4B (NS4B) - Products under Development by Companies 12 Nonstructural Protein 4B (NS4B) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Nonstructural Protein 4B (NS4B) - Companies Involved in Therapeutics Development 20 Gilead Sciences, Inc. 20 GlaxoSmithKline Plc 21 Inovio Pharmaceuticals, Inc. 22 Johnson & Johnson 23 Merck & Co., Inc. 24 Nonstructural Protein 4B (NS4B) - Drug Profiles 25 GSK-8853 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 INO-8000 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 PTC-512 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 PTC-725 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 PTC-971 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Small Molecule to Inhibit NS4B for Dengue and Yellow Fever Virus Infections - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecule to Inhibit NS4B Protein for HCV - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Nonstructural Protein 4B (NS4B) - Dormant Projects 33 Nonstructural Protein 4B (NS4B) - Discontinued Products 34 Nonstructural Protein 4B (NS4B) - Featured News & Press Releases 35 Apr 27, 2016: Inovio Partners with National Cancer Institute and Mayo Clinic to Initiate Hepatitis C Immunotherapy Clinical Trial 35 Oct 21, 2013: Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial 35 Jan 09, 2013: Inovio Pharma To Initiate Clinical Trial For Hepatitis C Therapeutic Vaccine 36 Oct 26, 2009: Wellcome Trust funds dengue fever research in Leuven 37 Aug 10, 2009: PTC Therapeutics Announced Achievement Of Major Milestone In Schering-Plough Hepatitis C Collaboration 38 Mar 20, 2006: Schering-Plough And PTC Therapeutics Announced Collaboration For Development Of PTC's Preclinical Hepatitis C Compounds 38 Appendix 40 Methodology 40 Coverage 40 Secondary Research 40 Primary Research 40 Expert Panel Validation 40 Contact Us 40 Disclaimer 4
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Assessment by Monotherapy/Combination Products, H1 2016 14 Number of Products by Stage and Mechanism of Action, H1 2016 15 Number of Products by Stage and Route of Administration, H1 2016 17 Number of Products by Stage and Molecule Type, H1 2016 19 Pipeline by Gilead Sciences, Inc., H1 2016 20 Pipeline by GlaxoSmithKline Plc, H1 2016 21 Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 22 Pipeline by Johnson & Johnson, H1 2016 23 Pipeline by Merck & Co., Inc., H1 2016 24 Dormant Projects, H1 2016 33 Discontinued Products, H1 2016 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.